Breast cancer treatment encompasses a variety of modalities such as surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy or immunotherapy.
Chemotherapy are drugs used to kill malignant cancer cells. These medications target tumour cell vulnerabilities compared to normal cells. The Achilles heel of cancer cells are that they need various mechanisms to grow faster, repair themselves, utilise certain nutritional pathways, increase their blood flow, reduce cell death signals and evade immunity. Chemotherapy and other kinds of anti-cancer therapy hinges on these and other mechanisms to attack and kill the cancer cell.
Not all breast cancer patients require chemotherapy. Chemotherapy if needed can be given at various stages of the treatment:
(A) Adjuvant setting (after surgery when there is no evidence of disease spread to other sites): This is to reduce the risk of recurrence and improve the overall survival by treating any cancer cells that may still be present but just cannot be picked up by blood or radiological test
(B) Neoadjuvant setting (before definitive surgery): This has some advantages, particularly for larger tumours. We are able to downstage the cancers, making them smaller, so that there is an option of breast conservation for some suitable patients. In addition, being able to assess the tumour response to drug treatment allows some adjustment to therapy for some groups of breast cancer patients. Patients who already have large locally advanced breast cancers affecting the skin, chest wall, or with large lymph nodes should have chemotherapy first to maximise the chance of clearance at surgery.Sometimes, a course of further chemotherapy may still be offered after surgery in certain subtypes of breast cancer and your doctor will discuss this with you
(C) Advanced setting: This is used as a first-line treatment strategy in certain situations when the cancer has already spread to distant organs and sites (stage IV disease)
Typically, chemotherapy regimens may take between three and six months, and are administered in ‘cycles’. Administering the medications with a rest of one to three weeks allows the patient’s own cells to recover before the next drug administration. Some cytotoxic cancer drug treatment is given as a short infusion, while some may take several hours. Almost all treatment is usually given in a comfortable outpatient setting in our clinic.
Side effects of chemotherapy vary depending on the drug type and regimen. However, these side effects can be generally well managed. We have a scalp cooling machine that can help to reduce the risk of hair loss but it works for only certain chemotherapy drugs. Please feel free to discuss this with your doctor to see if you are suitable to use it.
Sometimes in early stage cancers, the necessity of chemotherapy may not be very clear. In these cases, there are certain genomic tests done on your tumour tissue that can help in assessing the risk for recurrence and help you make a decision about chemotherapy. Your treating doctor will be able to help you understand when you need these tests.
Anti-cancer hormone therapy , also called endocrine therapy, uses drugs to target the estrogen (oestrogen) signalling that hormone-sensitive breast cancer cells need to drive their growth and multiplication.
Breast cancers that utilise this signalling pathway primarily are identified on the tumour cell staining as estrogen receptor positive (ER positive) and / or progesterone receptor positive (PR positive). This test uses an antibody test, staining the tumour cells with colour. The intensity and percentage of cells stained may be reflected in the pathology report.
There are many studies involving many cancer patients which have shown improved survival for women with hormone sensitive breast cancer taking these drugs for a period of time. Common oral medicines that are prescribed include tamoxifen for women before and after menopause and aromatase inhibitors such as anastrozole(Arimidex), exemestane (Aromasin), and letrozole (Femara) for postmenopausal women. These drugs are used in both early and advanced stages of breast cancer. There are also other hormone therapy used in the advanced cancer setting such as fulvestrant (Faslodex)which comes in the form of intra-muscular injections.Some types of hormonal therapy work by suppressing the ovaries from making hormones, either through surgery, radiotherapy or through medications. In general, the side effects of the hormonal therapy drugs vary depending on the type, but are usually well tolerated and easily managed.
To treat advanced breast cancer, the latest developments are a group of drugs known as CDK4/6 inhibitors (namely palbociclib (Ibrance) ribociclib (Kisqali) and abemaciclib (Verzenio) targeting the enzymes CDK4 and CDK 6 which are important in cell division. These oral drugs are used in combination with the hormonal therapy described above (aromatase inhibitors, tamoxifen, fulvestrant). These drugs have side effects which are tolerable and generally manageable. Your treating doctor will provide you with an in-depth discussion of the relevant side effects so you can better understand them.
Cellular growth and metabolism requires multiple signalling pathways. Cancer cells may sometimes hijack these signals to gain an advantage over normal cells, resulting in tumour cell proliferation.
One of the established targeted pathways for breast cancer is the HER2 (also known as erbB2) signalling pathway. About 20 to 25% of breast cancer cells amplify the HER2 gene in the cancer cell which then results in an excess of the HER2 growth promoting protein being expressed on it. This is like hyperactivating the cellular growth engine. These tumours are known as HER2-positive breast cancers. Such tumours are known to behave more aggressively, and tend to spread early to lymph nodes and other organs, including the brain.
Trastuzumab (Herceptin) is a monoclonal antibody directed against the HER2 protein. It was approved in 1998 to block this particular signalling pathway. It is usually given intravenously but there is now a subcutaneous formulation resulting in easier administration. When given with chemotherapy, it has resulted in high tumour response rates and better success rates in both the early and advanced stage settings.
Since then other HER2 targeting drugs have been approved, including ado-trastuzumab (T-DM1 or Kadcyla) and pertuzumab (Perjeta); both given intravenously and neratinib (Nerlynx) and lapatinib (Tykerb) both given orally. These drugs are used in different settings and stages of your breast cancer treatment and your treating doctor will be able to determine which is the best drug suited for you.
The side effects of anti-HER2 agents are generally mild but some can be more serious. For example trastuzumab, pertuzumab or ado-trastuzumab can cause heart weakening or heart failure and monitoring of the cardiac function is important during treatment.
Other targeted therapeutic agents against other pathways have also been developed for use in advanced breast cancer. These include the following:
(1) PARP inhibitors (olaparib[Lynparza], talazoparib[ Talzenna]): oral drugs approved for use in advanced breast cancers that are HER2-negative. These people should also carry a germline BRCA gene mutation (an inherited mutation in the BRCA gene that helps in DNA repair)
(2) PIK3CA inihibitor (alpelisib[Piqray]): this is an oral drug used in combination with the hormonal therapy drug fulvestrant (Faslodex) in hormone receptor-positive HER2-negative advanced breast cancers which carry a PIK3CA mutation. The PI3K/AKT/mTOR pathway is a signalling pathway for cellular growth and metabolism. Inhibition of this pathway can result in tumour suppression. About 30-40% of breast cancers have been found to have this PIK3CA gene mutation.
(3) mTOR inhibitors (everolimus [Affinitor]: an oral drug used in combination with exemestane (Aromasin) in hormone receptor-positive HER2-negative advanced breast cancers. By inhibiting the protein mTOR, it inhibits or slows down cell proliferation. It can also limit the growth of new blood vessels into tumours depriving it of nutrients.
All these targeted therapies have their own distinctive side effect profiles and your doctor will be able to help you decide which is best suited for your condition.
Immunotherapy drugs harness the body’s own immune system to recognise and kill cancer cells. This class of drugs when used in conjunction with chemotherapy have been found to be most effective in the subtype of triple-negative breast cancers (estrogen and progesterone receptors negative, HER2 negative).
Radiation therapy (or radiotherapy) uses high-energy X-rays (radiation) to treat breast cancer. Post-surgery radiotherapy is recommended after lumpectomy (breast conservation surgery) or in certain cases after a mastectomy when the risk of locoregional recurrence is high (such as if there are large tumours or heavy lymph node disease). Radiation therapy is typically given over a period of several weeks and through detailed planning of the radiation field, avoids the main organs as far as possible.
Radiotherapy is also a modality used in advanced cancer to treat certain conditions such as bone pains or if there is nerve compression in the spinal cord. Brain metastases from breast cancer would also often need radiotherapy. Focal radiation to selected tumour sites, called stereotactic radiotherapy, may be utilised in some situations to minimize side effects of treatment.
Early detection is the key to a faster recovery. You should seek the right oncologists and breast cancer specialists to assist you or your loved ones with the most suitable cancer treatments to treat your condition. These medical professionals will be able to diagnose the stages of your breast cancer, advise on the best treatment regime and possible side effects, and support you at every phase of your recovery process.
In choosing the right oncologist and breast cancer specialist, you need to consider their years of experience in the field, knowledge of the latest and most advanced procedures (including clinical trials) and ability to prescribe the most appropriate treatment regimes for your specific condition.
OncoCare’s team of oncologists have decades of specialist experience in the field of breast cancer. Our specialists are trained in the foremost oncology institutes in the world, including the Dana Farber Cancer Institute (Harvard Medical School) and the John Hopkins Medical Institute.
Senior Consultant, Medical Oncologist
MBBS (Singapore) – M.Med (Singapore) – MRCP (United Kingdom) – FAMS (Medical Oncology) – MHsc (Duke, USA)
Dr Wong Nan Soon has over 15 years of experience in diagnosing and managing a wide range of cancer. He specialises in breast cancer and gastrointestinal cancers, such as colon cancer, rectal cancer, anal cancer, biliary cancer, pancreatic cancer, liver cancer, GI stromal cancers (GIST), and neuroendocrine cancer. Dr Soon also has experience treating patients with lung cancer, kidney cancer, uterine cancer, cervical cancer, and ovarian cancer.
In 1994, he graduated from the Faculty of Medicine, National University of Singapore and earned his Master’s in Internal Medicine and Membership of the Royal College of Physicians in the United Kingdom. In 2003, he completed advanced specialty training in general medical oncology.
Following his graduation, he completed a 1 year clinical fellowship sub-specialising in breast medical oncology in Canada, where he trained under Professor Kathleen Pritchard, world renowned breast oncologist.
Senior Consultant, Medical Oncologist
MBBS (Singapore) – M.Med (Singapore) – MRCP (United Kingdom) – FAMS (Medical Oncology)
Dr. Tan Sing Huang is a Senior Consultant Medical Oncologist who has more than 16 years experience in managing a wide range of cancers. Prior to joining OncoCare Cancer Centre, she held the position of Senior Consultant in the Department of Hematology-Oncology National University Cancer Institute, Singapore (NCIS). She was also Assistant Professor, Yong Loo Lin School of Medicine, National University of Singapore.
During her work at NCIS, she had continued to take care of patients with a wide variety of cancers, including Breast cancers, Gynecological cancers, Lung cancers and Gastrointestinal cancers (colon, rectum, pancreas, liver, gastric) although her primary interest is in Women’s Cancers. As a result of her clinical efforts in NUH, she was awarded the Sunny Side-Up and Sunny Side-Up WOW Awards for exemplary patient feedback.
She led the Senior Residency Education division in NCIS as its Program Director since 2012 till 2016, served as Co-Chairman for the NCIS Clinical Competency Committee and also as panel member for national selection of Medical Oncology trainees. In addition, she participated as an examiner for undergraduate final medical exams. As a result of her contributions to education, she was awarded the NUH Teaching Excellence Award in 2014.
She held the post of Vice President of the Singapore Society of Oncology since 2013 till 2018.
She is also a long-standing current active Committee Member and more recently Deputy Chair of the National Healthcare Group Domain-Specific Ethics Review Board since 2020 which reviews Medical Oncology clinical trial protocols for the hospitals.
She was also principal investigator of several multi-center studies investigating new investigational drugs in HER2-positive breast cancers as well as being co-investigator of several multi-centre clinical trials in lung, colorectal and breast cancers.
Her interest in translational research led to spending time with the RUNX research group in Singapore under a National Medical Research-Singapore (NMRC) Totalisator Medical Research Fellowship Award. She then went to Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre in Baltimore in 2006-2007 where she was involved in epigenetics research and also gained clinical experience from attachments with the Breast Cancer Division of Johns Hopkins Medical Institute.
She has been awarded the Research-Investigator-Scientist Enabler (RISE) Grant Scheme Award from 2008 to 2010, and the Junior Investigator Protected Time Award in 2011.She won a Merit Award for her Oral Presentation at the 10th International Conference of The Asian Clinical Oncology Society in Seoul on oncogenic mutation profiling changes pre- and post-chemotherapy in breast cancers. She was given the National Medical Research Council Clinician Investigator Salary Support Program (CISSP) Award from 2012 to 2014. She went on to obtain a number of independent grants since 2008 studying methylation patterns, high-throughput oncogenic mutation profiling and the effects of chemotherapy on cognition in cancer patients.
She has contributed chapters on chemotherapy treatment of metastatic breast cancer in international textbooks such as Diseases of the Breast. In addition, she has written and contributed to publications which have appeared in local and international journals including Clinical Cancer Research and Annals of Oncology.
She has also given many local and overseas talks as an invited speaker including in China, Vietnam and Brunei. She has also chaired conferences and been an invited speaker for both local and overseas conferences. She is fluent in English, Mandarin and Hokkien and is able to speak some Malay and Bahasa. She has taken care of patients from many regional and overseas regions including Indonesia, Vietnam, Myanmar, China, Bangladesh, Sri Lanka, India and Russia.
Senior Consultant, Medical Oncologist
MBBS (Singapore) – M.Med (Singapore) – MRCP (United Kingdom) – FAMS (Medical Oncology)
Dr Peter Ang graduated from the National University of Singapore in 1991 and then earned his Master of Medicine in the United Kingdom in 1997. He was awarded the Ministry of Health Manpower Development Programme (HMDP) Scholarship to train at Dana Farber Cancer Institute, where he focused on general oncology with a focus on breast cancer and cancer genetics.
He is recognised for his leadership and expertise as a breast cancer specialist doctor, and was the leading cancer specialist of the Breast Cancer Workgroup (2002) for National Cancer Centre, Singapore and Singhealth cluster. He is involved in providing comprehensive oncology information and excellent care for patients with a wide range of cancers including lung cancer, stomach cancer, colorectal cancer, lymphoma, kidney cancer, breast cancer, ovary cancer, uterus cancer, and cervix cancer. He has also been actively involved in clinical and translational cancer research for many years, in breast, colon, lung and other cancers.
Breast cancer is the top cancer in women both in the developed and the developing world. Over the past 40 years, the incidence of breast cancer in Singapore has more than doubled from 25 to 65 per 100,000 women. It accounts for about 1 in 3 cancers in women locally, with rates beginning to increase after the age of 40yo. However, young onset breast cancer occurring in women in their 20s and 30s can still happen and the number of reported cases is increasing in this age group. Notably, men can also get breast cancer but it is far less common.
The most common sign of breast cancer is a lump which is most commonly painless, but can be tender or painful too. Other signs include nipple retraction, nipple discharge, swollen lymph nodes in the underarm area (can occur even before feeling a breast mass), swelling of all or part of the breast, skin redness over the breast which can resemble inflammation and/or skin dimpling which looks like an orange peel (peau d’orange).
The key is early detection because when found at an early stage, it is highly curable and treatment can be minimized. When found at stage 0, chemotherapy can even be avoided.
Breast screening is important as early detection is the key to finding cancers at an earlier stage when treatments can be less complex and result in a better outcome.
Mammograms are the mainstay of screening. It is a simple test which uses x-rays to take pictures of the breasts at various angles and requires compression of the breasts between paddles to reduce the thickness. The dose of radiation is very low and consequently there is little health risk. An abnormal finding on a mammogram does not automatically mean one has cancer and most of these turn out to be no cause for worry.
50-69yo- mammogram once every 2 years
40-49yo-please discuss with your doctor about the benefits, limitations and potential risks. If you decide to do it, have it done annually
Although breast self-examination is now no longer part of formal screening recommendations, one should still be familiar with the normal look and feel of one’s breasts so that one is able to recognise any changes in a timely manner.
MRI breasts can be added as an adjunct to mammogram to screen women who are of high risk such as those who carry a genetic mutation (eg. a BRCA gene mutation) which confers an increased lifetime risk for breast cancer
Breast cancer typically starts when abnormal cells in the breast start to grow uncontrollably forming a tumour. Most often it arises from the milk ducts of the breast (ductal cancers) or less commonly from the glands that make the milk (lobular cancers). There are other kinds of breast cancers such as malignant phyllodes tumours, or tumours which start in other kinds of tissue residing in the breast such as lymphomas (lymphatic tissue) or sarcomas (connective tissue, blood vessels). Paget’s disease is a rare form of breast cancer which arises in and around the nipple.
The subtypes of breast cancer based on the appearance of the tissue obtained upon biopsy include invasive ductal cancers which comprise about 80%, with the frequency of invasive lobular cancers being much lower (about 10%). Breast cancers can also occur very early such as ductal carcinoma in-situ (DCIS) tumours. DCIS are stage 0 cancers and do not have the ability to spread to distant sites away from the breast. They have an extremely good prognosis.
There are various risk factors but many people who develop breast cancer do not have any of them. Also there is no specific risk factor which is the direct cause and often it may be a combination of a few or none at all. Some of the risk factors which increase one’s risk are as follows:
Age – the risk increases as one gets older
Gender- it is 100x more common in women than in men
Estrogen levels- higher endogenous estrogen levels are associated with increased risk especially for hormone receptor-positive breast cancer
Dense breasts- those with dense breasts seen on mammogram are at increased risk
Early age when menses first started or late age at menopause
Women who have not had any children before
Women who had their first child at a later age
A personal history of breast cancer
A family history of breast cancer in first-degree relatives (mother, sister, father) especially if diagnosed at a young age
Those who carry an inherited genetic mutation which predisposes one to breast cancer
Exposure to radiation of the chest as a form of treatment for other cancers like Hodgkin lymphoma or due to unforeseen circumstances particularly at a young age can increase the risk
Lifestyle changes can help in reducing or eliminating some of the risk factors such as:
Breastfeeding- a protective effect has been shown in some studies
Regular physical activity to maintain a healthy weight can provide some protection
Limit or abstain from alcohol intake
There is no strong evidence of a link between diet and breast cancer but a healthy and well balanced diet which includes vegetables, fish, and less red meat is beneficial for general health and well-being.
Knowing the stage of the breast cancer is paramount to understanding its treatment strategy and prognosis. Staging is based on the tumour size, spread to regional lymph nodes and distant organs. It is also determined by the estrogen and progesterone receptor status, HER2 status and grade of the cancer (how different the cells look compared to normal cells). Stage 0 refers to non-invasive DCIS, stage I-III refers to invasive breast cancer which is confined to the breast and/or nearby (regional) lymph nodes, and stage IV refers to breast cancer that has spread to distant organs and sites.